Myriad Genetics, Inc. (Nasdaq: MYGN) announced that its Tumor BRACAnalysis CDx companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in ovarian cancer patients. Data from this new study were presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting in Madrid, Spain. "Several previous clinical studies have demonstrated that patients with germline or somatic BRCA1/2 ...
Read More
You have just read an article categorized health
titled Myriad Genetics Presents Tumor BRACAnalysis CDx Study.
Written by:
editor -
Monday, September 29, 2014
There are currently no comments for "Myriad Genetics Presents Tumor BRACAnalysis CDx Study"
Post a Comment